ÄúÏÖÔÚµÄλÖÃÊÇ£ºÊ×Ò³ > ½¡¿µÐÂÎÅ > ½¡¿µ×ÊѶ > °¢·¨ÌæÄᡪ¡ª±»³¤Æڵ͹ÀµÄ·Î°©°ÐÏòÒ©

°¢·¨ÌæÄᡪ¡ª±»³¤Æڵ͹ÀµÄ·Î°©°ÐÏòÒ©

ʱ¼ä£º2019-07-01 14:28  À´Ô´£ºÍøÂçתÔØ  ÔĶÁ´ÎÊý£º ¸´ÖÆ·ÖÏí ÎÒÒªÆÀÂÛ

       ËäȻĿǰ·Î°©ÉÐÎÞ·¨³¹µ×ÖÎÓú£¬µ«Ëæ×ÅÔ½À´Ô½¶à¿¹°©Ò©µÄ³öÏÖ£¬Í¨¹ý³¤ÆÚÖÎÁÆ¿ØÖÆÖ×Áö½øÕ¹£¬½«²»ÖÎÖ®Ö¢±ä³É“ÂýÐÔ²¡“ÒѳÉΪÁË¿ÉÄÜ£¬ÆäÖаÐÏòÒ©EGFR-TKIµÄÓÃÒ©Ñ¡Ôñ¾ÍÓÈΪ¹Ø¼ü£¬¶ø´ÓÁÙ´²Êý¾ÝÀ´¿´£¬¿ÉÒÔ˵£¬µÚ¶þ´ú°ÐÏòÒ©°¢·¨ÌæÄáÊÇÒ»¸ö³¤ÆÚ±»µÍ¹ÀµÄ°ÐÏòÒ©¡£

¡¡¡¡Ëæ׿ª·ÇÌæÄá¡¢°¢·¨ÌæÄáºÍ°ÂÏ£ÌæÄáµÈÒ»´úÓÖÒ»´ú°ÐÏòÒ©EGFR-TKIµÄÓ¿ÏÖ£¬Ö×Áöϸ°ûÒѾ­Äܱ»¾«×¼“ɱÃ𔣬¿É°ÐÏòÒ©ÎïÑ¡Ôñ½Ï¶à£¬µ½µ×ºÎÖÖÖÎÁÆ˳ÐòºÍÓÃÒ©×éºÏÄÜ´øÀ´¸ü³¤ÆÚÉú´æÄØ?

¡¡¡¡ÀíÂÛÉÏ£¬Õë¶ÔÍíÆÚEGFRÍ»±äµÄ·ÇСϸ°û·Î°©£¬ÁÙ´²Í¨³£½¨ÒéÒ»´ú»ò¶þ´ú°ÐÏòÒ©ÏÈÐУ¬Èç¹û»¼Õß·¢ÉúÄÍÒ©ÐÔT790MÍ»±ä£¬Ôò»»Èý´ú°ÐÏòÒ©°ÂÏ£ÌæÄá¼ÌÐøÖÎÁÆ¡£ÒÔ¼ª·ÇÌæÄá¡¢°¢·¨ÌæÄáΪ´ú±íµÄÒ»¡¢¶þ´ú°ÐÏòÒ©EGFR-TKIµÄÎÊÊÀ£¬Í»ÆÆÁË´«Í³·ÅÁÆ¡¢»¯ÁƵľÖÏÞ£¬Ê¹µÃÍíÆÚEGFRÍ»±ä·Î°©»¼ÕßµÄÉú´æÆÚÏÔÖøÑÓ³¤£¬²»¹ýÖÎÁƺó×ܻ᲻¿É±ÜÃâµØ²úÉúÄÍÒ©£¬µ¼ÖÂÖ×ÁöÔٴνøÕ¹¡£

¡¡¡¡Ñо¿ÏÔʾ£¬ÔÚ½ÓÊÜÒ»´ú»ò¶þ´ú°ÐÏòÒ©ÖÎÁƺ󣬴óÔ¼50%-60%µÄ»¼Õß»á³öÏÖT790MÄÍÒ©Í»±ä[1]£¬µ«¶ÔÓÚ´ó¶àÊý·Î°©»¼ÕßÀ´Ëµ£¬Èç½ñÓÐÁËÈý´ú°ÐÏòÒ©°ÂÏ£ÌæÄáÕâ¸öרÃÅ´¦ÀíT790MÍ»±äµÄ“ÐÂÎäÆ÷”£¬¾ÍËã·¢ÉúT790MÄÍÒ©Í»±ä£¬»¼ÕßµÄÉúÃüÔÚÏ൱³¤µÄÒ»¶Îʱ¼äÄÚ»¹ÄÜ“½ÓµÃס”¡£

¡¡¡¡ÄÇô£¬ÔÚ¿ªÊ¼°ÐÏòÒ©ÖÎÁÆʱ£¬»¼Õßµ½µ×¸ÃÑ¡Ò»´ú¡¢»¹ÊǶþ´ú°ÐÏòÒ©ÄØ?

¡¡¡¡²»ÉÙ»¼Õß±íʾ£¬¿ÉÄÜ»¹ÊÇÊ×Ñ¡Ïñ¼ª·ÇÌæÄá¡¢¶òÂåÌæÄáµÈÒ»´ú°ÐÏòÒ©£¬Ô­ÒòÔÚÓÚ¹úÄÚÉÏÊÐÔ硢ʹÓÃÈËÊý¶à£¬¶ø¶þ´ú°ÐÏòÒ©Ïà¶ÔÉÏÊнÏÍí£¬ÖªÏþÂʲ»¸ß¡£

¡¡¡¡¿ÉÆ«Æ«¾ÍÊÇÕâÑùÒ»¿î“µÍµ÷”µÄ°ÐÏòÒ©£¬×î½üÔÚÁÙ´²±íÏÖÉÏ·¢ÉúÁË“´ó·´×ª”£º

¡¡¡¡2018ÄêÅ·ÖÞÁÙ´²Ö×ÁöЭ»áÄê»áÉϹ«²¼µÄÒ»ÏîÈÕ±¾µÄÕæʵÊÀ½çÑо¿ÏÔʾ[2]£¬Í¬Ñù¶¼ÊÇʹÓÃÈý´ú°ÐÏòÒ©°ÂÏ£ÌæÄᓽÓÁ¦”T790MÄÍÒ©Í»±ä£¬¶þ´ú°ÐÏòÒ©°¢·¨ÌæÄáÏÈÐеÄÁÆЧ¾¹±ÈÒ»´úÏÈÐиüÓÐÓÅÊÆ¡£ÔÚÈë×éµÄ111λ»¼ÕßÖУ¬°¢·¨ÌæÄáÐò¹á°ÂÏ£ÌæÄáµÄÖÎÁÆ˳Ðò£¬°ÂÏ£ÌæÄáµÄ¿Í¹Û»º½âÂÊ´ï82.9%£¬Ò²¾ÍÊÇ˵£¬Ô¼ÓÐ82.9%ÐÂÈ·Õï·Î°©µÄ»¼ÕßÔÚʹÓÃÉÏÊöÖÎÁÆ˳Ðòºó£¬Ö×ÁöÌå»ý·¢ÉúÁËËõС¡£Ïà±È֮ϣ¬“Ò»´ú°ÐÏòÒ©Ðò¹á°ÂÏ£ÌæÄᔵÄÖÎÁÆ˳Ðò£¬°ÂÏ£ÌæÄáµÄ¿Í¹Û»º½âÂʽöÓÐ53.9%¡£

¡¡¡¡Æäʵ£¬Õâ²¢²»ÊÇ°¢·¨ÌæÄáµÚÒ»´ÎÁîÈË“¹ÎÄ¿Ïà¿´”¡£È¥Äê¹ú¼ÊȨÍþѧÊõÆÚ¿¯¡¶Future Oncology¡·¹«²¼µÄÒ»ÏîÃûΪGioTagµÄÕæʵÊÀ½çÑо¿ÏÔʾ[3]£¬»¼ÕßÔÚÖÎÁƳõÆÚ¾ÍʹÓ𢷨ÌæÄᣬ³öÏÖT790MÄÍÒ©ºóÔÙʹÓðÂÏ£ÌæÄᣬÖÐλÖÎÁÆʱ¼ä´ï27.6¸öÔÂ;Èç¹û»¼Õß´æÔÚ19ÍâÏÔ×Óȱʧͻ±ä(Del19)£¬ÁÙ´²»ñÒæ¸üÏÔÖø£¬ÖÐλÖÎÁÆʱ¼ä¿É´ï30.3¸öÔÂ;¶øÒÔ¸ü¹ã·ºµÄÑÇÖÞ»¼ÕßÈËȺµÄÊý¾ÝÀ´¿´£¬²ÉÓÃÕâÖÖ˳ÐòÓÃÒ©×éºÏºó£¬ÖÐλÖÎÁÆʱ¼ä¾¹¸ß´ï46.7¸öÔÂ!¼´½«½ü4ÄêµÄÉú´æʱ¼ä!

¡¡¡¡(¹ú¼ÊȨÍþѧÊõÆÚ¿¯¡¶Future Oncology¡··¢²¼°¢·¨ÌæÄáÐò¹á°ÂÏ£ÌæÄáÖÎÁƵÄÕæʵÊÀ½çÑо¿Êý¾Ý)

¡¡¡¡½Ó½ü4Ä꣬Õâ¸öÊý×Ö¶ÔÓÚ´ó¶àÊýÍíÆÚ·ÇСϸ°û·Î°©»¼ÕßÀ´Ëµ£¬Òâζ×ŶÔδÀ´¸üÓГÅÎÍ·”£¬ËûÃDz»½ö½öÄܺÍÕý³£ÈËÒ»ÑùåÞÍä¡¢Âò²Ë¡¢Ìø¹ã³¡Î裬ÉõÖÁ»¹Óлú»á¿´µ½º¢×Ó´óѧ±ÏÒµ¡¢½á»éÉú×Ó…… 40¶à¸öÔ¡¢1400¶àÌ죬»¼ÕßÓиü³¤µÄʱ¼ä£¬Äܹ»“Ô²¸ü¶àµÄÃΔ¡£

¡¡¡¡³ýÁËÉú´æÆÚµÄÑÓ³¤£¬Éú»îÖÊÁ¿µÄÌáÉýÒ²ÊǸÃÑо¿µÄÁíÒ»ÖØÒª½áÂÛ¡£GioTagÑо¿½á¹û±íÃ÷£¬»¼Õß¾­°¢·¨ÌæÄáÖÎÁƺó³öÏÖT790MÄÍÒ©£¬ÔÙʹÓðÂÏ£ÌæÄᣬÄܹ»ÍƳٻ¯ÁƵÄʱ¼ä[4]£¬ÔÚÒ»¶¨Ê±ÏÞÄÚ±£Ö¤ÁË»¼ÕßµÄÉú»îÖÊÁ¿¡£

¡¡¡¡ÎÒÃdz£Ëµ£¬Ñ¡ÔñÒ»ÖÖÖÎÁÆ·½°¸ÐèÒªÁ˽âÒ©ÎïµÄÁÙ´²Êý¾Ý£¬µ«ÆäʵÁ˽âÑо¿±³ºóµÄÁÙ´²±³¾°Ò²Í¬µÈÖØÒª¡£

¡¡¡¡²»Í¬ÓÚ´ó¼Ò±È½ÏÊìϤµÄ“˫ä¶ÔÕÕ”ÁÙ´²ÊÔÑ飬ÒÔÉÏÁ½Ïî°¢·¨ÌæÄáµÄÊý¾Ý¶¼Ô´×Ô“ÕæʵÊÀ½çÑо¿”¡£

¡¡¡¡Ê²Ã´Òâ˼ÄØ?“˫ä¶ÔÕÕ”µÄÁÙ´²ÊÔÑéÓÐ×ÅÑϸñµÄÉè¼ÆºÍ¹ÜÀí£¬¸ü¶àµØºâÁ¿Ò©ÎïÔÚÀíÏ뻯¡¢±ê×¼»¯µÄ״̬϶Ի¼ÕßµÄÖÎÁÆЧ¹û£¬ÇÒ¶ÔÈë×黼ÕßÓÐÒ»¶¨µÄɸѡÌõ¼þ;¶øÕæʵÊÀ½çÑо¿ÔòÏà¶ÔÔÚ¸ü´óµÄ»¼ÕßÑù±¾Á¿»ù´¡ÉÏ£¬¸ù¾Ý»¼ÕßµÄʵ¼Ê²¡Çé»Ø¹ËÒ©ÎïµÄÖÎÁÆЧ¹û¡£¿ÉÒÔ˵£¬ÕâÁ½ÏîÑо¿·´Ó³³ö»¼ÕßÔÚÏÖʵ»·¾³ÖÐ˳ÐòʹÓ𢷨ÌæÄáºÍ°ÂÏ£ÌæÄáµÄÕæʵÁÆЧ¡£

¡¡¡¡Èç´Ë¿´À´£¬°¢·¨ÌæÄáµÄÁÆЧȷʵ³¤ÆÚ±»“µÍ¹À”¡£Ò²ÐíÓÐÈË»á˵£¬¼´±ãÉÏÊöÓÃÒ©×éºÏÁÆЧÏÔÖø£¬µ«°¢·¨ÌæÄáƤÕî¡¢¸¹ÐºµÈ¸±×÷ÓÃÄÑÒÔºöÊÓ¡£ÊÂʵÉÏ£¬ÏñƤÕî¡¢¸¹ÐºÕâÀั×÷Óò¢·Ç²»¿É¿ØÖÆ£¬¶øÇҿɸù¾Ý»¼ÕßµÄÄÍÊÜÇé¿öµ÷Õû¼ÁÁ¿£¬¶ø²»»á¶ÔÖÎÁÆЧ¹û²úÉúÓ°Ïì[5] ¡£ÊÂʵÉÏ£¬ÓÃÒ©ÐèҪƽºâÖÎÁÆ»ñÒæºÍ·çÏÕ¡£¶Ô±ÈÆð³¤ÆÚÉú´æ“ÕâһͷµÈ´óÊ”£¬°¢·¨ÌæÄá¿É¿Ø¡¢¿É¹ÜÀíµÄ¸±×÷ÓÃÏà¶ÔÊǸüÇá΢µÄÎÊÌâ¡£ ±Ï¾¹£¬ÄܶàÉú´æÒ»Ìì¡¢ÄÜÉÙÒ»Ì컯ÁÆ£¬¶Ô¹ã´óEGFR»ùÒòÍ»±äµÄÍíÆÚ·ÇСϸ°û·Î°©»¼ÕßÀ´Ëµ¾ÍÊÇ“Ó²µÀÀ픡£Ò½Ñ§ÔÚÇ°½ø£¬»îµÃ¸ü³¤Òâζ×ÅδÀ´½«Óиü¶à»ú»á½ÓÊܸüеÄÖÎÁÆ£¬¼ÌÐøÓë·Î°©×ö¶·Õù£¬ÎÒÃÇÒª×öµÄ¾ÍÊǾ¡¿ÉÄܵػîµÄ³¤¡¢»îµÄºÃ£¬µÈ×ÅÕâÒ»ÌìµÄµ½À´¡£

¡¡¡¡²Î¿¼ÎÄÏ×£º

¡¡¡¡[1] Tanaka K, Nosaki K, Otsubo K, et al. Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring EGFR mutations. Oncotarget. 2017;8(40):68123–68130. Published 2017 Jul 12. doi:10.18632/oncotarget.19243

¡¡¡¡[2] https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Which-is-better-EGFR-TKI-followed-by-osimertinib-between-afatinib-and-gefitinib-erlotinib

¡¡¡¡[3] Hochmair, Maximilian & Morabito, Alessandro & Hao, Desiree & Yang, Cheng-Ta & A Soo, Ross & Yang, James Chih-Hsin & Gucalp, Rasim & Halmos, Balazs & Wang, Lara & Golembesky, Amanda & Märten, Angela & Cufer, Tanja. (2018). Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: An observational study. Future Oncology. 14. 10.2217/fon-2018-0711.

¡¡¡¡[4] www.boehringer-ingelheim.com/press-release/giotagsequencingresults

¡¡¡¡[5] Halmos, Balazs & Tan, Eng-Huat & A. Soo, Ross & Cadranel, Jacques & Ki Lee, Min & Foucher, Pascal & Hsia, Te-Chun & Hochmair, Maximilian & Griesinger, Frank & Hida, Toyoaki & Kim, Edward & Melosky, Barbara & Märten, Angela & Carcereny, Enric. (2018). Impact of Afatinib Dose Modification on Safety and Effectiveness in Patients with EGFR Mutation-Positive Advanced NSCLC: Results from a Global Real-World Study (RealGiDo). Lung Cancer. 127. 10.1016/j.lungcan.2018.10.028.

ÍƼöÄÚÈÝ
ÈȵãÄÚÈÝ